Posted by Michael Wonder on 28 Nov 2019
Health Canada approves Ofev (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
27 November 2019 - Boehringer Ingelheim announced today that Health Canada has approved Ofev (nintedanib) as the first and only treatment indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).
Interstitial lung disease (ILD) is the leading cause of death related to systemic sclerosis (SSc) or scleroderma, accounting for 35 per cent of all disease-related deaths.
This new approval changes the treatment paradigm for SSc-ILD, giving patients an opportunity to slow the progression of decline in lung function where no Health Canada approved options previously existed.
